Point72 Asset Management
XLRN

Point72 Asset Management’s Acceleron Pharma XLRN Stock Holding History

Point72 Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-63,401
Closed -$6.04M – 1161
2020
Q2 		$6.04M Buy
+63,401
New +$6.11M 0.04% 448
2020
Q1 		– Sell
-272,841
Closed -$14.5M – 1192
2019
Q4 		$14.5M Buy
272,841
+222,585
+443% +$10.1M 0.08% 317
2019
Q3 		$1.99M Sell
50,256
-725,512
-94% -$31.5M 0.01% 592
2019
Q2 		$31.9M Buy
775,768
+278,068
+56% +$11.5M 0.17% 159
2019
Q1 		$23.2M Sell
497,700
-247,400
-33% -$10.9M 0.11% 218
2018
Q4 		$32.4M Buy
745,100
+732,072
+5,619% +$36.6M 0.16% 169
2018
Q3 		$746K Buy
+13,028
New +$640K ﹤0.01% 883
2017
Q4 		– Sell
-72,900
Closed -$2.72M – 1158
2017
Q3 		$2.72M Buy
+72,900
New +$2.53M 0.01% 633
2017
Q2 		– Sell
-182,741
Closed -$4.84M – 1058
2017
Q1 		$4.84M Buy
+182,741
New +$4.82M 0.03% 532

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Point72 Asset Management's XLRN Position: Q3 2020 in Review

Point72 Asset Management sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 63,401 shares — an estimated $6.04M sold.

Point72 Asset Management first reported a position in XLRN in Q1 2017 and held it in 9 quarters. The position peaked at $32.4M in Q4 2018. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

  • Point72 Asset Management reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
  • Point72 Asset Management sold 63,401 Acceleron Pharma shares in Q3 2020, an estimated $6.04M.
  • Point72 Asset Management first reported a position in Acceleron Pharma in Q1 2017 and held it in 9 quarters.
  • Point72 Asset Management's Acceleron Pharma position peaked at $32.4M in Q4 2018.
  • 238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Point72 Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.